These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 4348519)

  • 21. The impact of scientific models on clinical psychopharmacology: an internist's view.
    Hollister LE
    Semin Psychiatry; 1972 Aug; 4(3):265-9. PubMed ID: 4374762
    [No Abstract]   [Full Text] [Related]  

  • 22. A pharmacological model of the pathophysioloyg of schizophrenia.
    Klawans HL; Westheimer R; Goetz CC
    Dis Nerv Syst; 1975 May; 36(5):267-75. PubMed ID: 166804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy of schizophrenia.
    Ban TA
    Curr Psychiatr Ther; 1976; 16():163-75. PubMed ID: 991627
    [No Abstract]   [Full Text] [Related]  

  • 24. [Etiology of schizophrenia: neurochemical aspects].
    de las Cuevas Castresana C; González de Rivera JL
    Neurologia; 1994 Feb; 9(2):54-9. PubMed ID: 7515627
    [No Abstract]   [Full Text] [Related]  

  • 25. [Neurochemistry and tranquillisers].
    Valenzuela A
    Munch Med Wochenschr; 1972 Jun; 114(25):1212-4. PubMed ID: 4341634
    [No Abstract]   [Full Text] [Related]  

  • 26. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.
    Snyder SH
    Am J Psychiatry; 1976 Feb; 133(2):197-202. PubMed ID: 1251927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biological research on schizophrenia. Dopamine activity of the brain in relation to the "amphetamine model"].
    Fog R; Munkvad I; Randrup A
    Ugeskr Laeger; 1976 Aug; 138(34):2039-41. PubMed ID: 823674
    [No Abstract]   [Full Text] [Related]  

  • 29. Psychotropic drugs used in the management of schizophrenia.
    Bueno JR; Himwich HE
    Int J Neurol; 1967; 6(1):77-93. PubMed ID: 5630202
    [No Abstract]   [Full Text] [Related]  

  • 30. Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity.
    Farley IJ; Shannak KS; Hornykiewicz O
    Adv Biochem Psychopharmacol; 1980; 21():427-33. PubMed ID: 6155058
    [No Abstract]   [Full Text] [Related]  

  • 31. Psychoactive drugs and brain neurochemical transmitters.
    Valzelli L
    Arch Int Pharmacodyn Ther; 1972 Apr; 196():Suppl 196:221+. PubMed ID: 4342945
    [No Abstract]   [Full Text] [Related]  

  • 32. Proceedings: Differentiation between neuroleptic antipsychotic properties and side effects by subgroups of dopaminergic neurons.
    Bunney BS; Aghajanian GK
    Psychopharmacol Bull; 1974 Oct; 10(4):17-8. PubMed ID: 4473793
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of antipsychotic drugs on reproductive functions.
    Blair JH; Simpson GM
    Dis Nerv Syst; 1966 Oct; 27(10):645-7. PubMed ID: 4380665
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathophysiology of schizophrenia and the striatum.
    Klawans HL; Goetz C; Westheimer R
    Dis Nerv Syst; 1972 Nov; 33(11):711-9. PubMed ID: 4266033
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of methiothepin on cerebral monoamine neurons.
    Lloyd KG; Bartholini G
    Adv Biochem Psychopharmacol; 1974; 10():305-9. PubMed ID: 4846546
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacological experience with phenothiazines and butyrophenones].
    Cuisset P; Roujas F
    Ann Anesthesiol Fr; 1976; 17(9):1025-32. PubMed ID: 13687
    [No Abstract]   [Full Text] [Related]  

  • 37. Dopamine in schizophrenia.
    Heritch AJ
    Am J Psychiatry; 1992 Nov; 149(11):1620-1. PubMed ID: 1415847
    [No Abstract]   [Full Text] [Related]  

  • 38. Alterations of serotonin transmission in schizophrenia.
    Abi-Dargham A
    Int Rev Neurobiol; 2007; 78():133-64. PubMed ID: 17349860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).
    Hornykiewicz O
    Br Med Bull; 1973 May; 29(2):172-8. PubMed ID: 4356552
    [No Abstract]   [Full Text] [Related]  

  • 40. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.